Report the prespecified third interim analysis (IA) of efficacy and safety outcomes in study COU–AA–302. The updated IA of study COU–AA–302 in patients with mCRPC without prior chemotherapy confirms that abiraterone delays disease progression, pain, and functional deterioration and has clinical benefit with a favourable safety profile, including in patients treated for ≥24 mo.

READ FULL ARTICLE Curated publisher From Mdlinx